Belpointe Asset Management LLC Increases Stock Holdings in Axon Enterprise, Inc $AXON

Belpointe Asset Management LLC lifted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 108.5% in the second quarter, Holdings Channel.com reports. The firm owned 1,172 shares of the biotechnology company’s stock after buying an additional 610 shares during the period. Belpointe Asset Management LLC’s holdings in Axon Enterprise were worth $970,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TCTC Holdings LLC boosted its holdings in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC boosted its holdings in Axon Enterprise by 132.0% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 33 shares during the period. Banque Transatlantique SA purchased a new position in Axon Enterprise during the 1st quarter valued at $31,000. Catalyst Capital Advisors LLC purchased a new position in Axon Enterprise during the 1st quarter valued at $32,000. Finally, Flaharty Asset Management LLC purchased a new position in Axon Enterprise during the 1st quarter valued at $33,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of AXON stock opened at $714.60 on Wednesday. Axon Enterprise, Inc has a twelve month low of $420.49 and a twelve month high of $885.91. The stock has a market capitalization of $56.10 billion, a price-to-earnings ratio of 176.44, a P/E/G ratio of 28.02 and a beta of 1.41. The stock has a fifty day simple moving average of $757.21 and a two-hundred day simple moving average of $710.53. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s quarterly revenue was up 32.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity

In related news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $743.64, for a total transaction of $7,436,400.00. Following the completion of the sale, the chief executive officer directly owned 3,043,982 shares in the company, valued at $2,263,626,774.48. This represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 49,932 shares of company stock worth $37,978,216 over the last ninety days. 5.70% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AXON shares. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a report on Saturday, September 27th. UBS Group restated a “neutral” rating and set a $840.00 price objective (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Raymond James Financial restated an “outperform” rating and set a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. JMP Securities restated a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. Finally, Piper Sandler started coverage on Axon Enterprise in a report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 price objective for the company. Fourteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $841.64.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.